News Kabra Drugs Limited

Equities

524322

INE323K01017

Market Closed - Bombay S.E. Other stock markets 06:00:55 2024-06-24 EDT			5-day change	1st Jan Change
7.91 ^INR	0.00%		0.00%	+46.75%

05-30	Kabra Drugs Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	CI
02-14	Kabra Drugs Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	CI

Summary

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Kabra Drugs Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	05-30	CI
Kabra Drugs Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	02-14	CI
Kabra Drugs Limited announced that it expects to receive INR 56.905 million in funding	01-22	CI
Kabra Drugs Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	11-13	CI
Kabra Drugs Limited Approves to Shift Registered Office	23-09-30	CI
Kabra Drugs Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-14	CI
Kabra Drugs Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023	23-06-08	CI
Kabra Drugs Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	23-02-14	CI
Kabra Drugs Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	22-11-14	CI
Kabra Drugs Limited Announces Resignation of Muralidharan R as Director	22-11-02	CI
Kabra Drugs Limited Announces Board Appointments	22-09-30	CI
Kabra Drugs Limited Reports Earnings Results for the First Quarter Ended June 30, 2022	22-08-13	CI
Kabra Drugs Limited Announces Executive Changes	22-07-07	CI
Kabra Drugs Limited Announces Appointment of K.N Anand as Additional Director (Independent Director)	22-06-09	CI
Kabra Drugs Limited Announces Resignation of Churchil Durai M Jebastine as Director	22-05-30	CI
Kabra Drugs Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2022	22-05-30	CI
Kabra Drugs Limited Reports Earnings Results for the Full Year Ended March 31, 2022	22-05-30	CI
Kabra Drugs Limited Announces Resignation of Pritam Paul as Secretary and Compliance Officer	22-04-18	CI
Kabra Drugs Limited Appoints Pritam Paul as Company Secretary and Compliance Officer	22-03-18	CI
Kabra Drugs Limited Announces the Resignation of Company Secretary and Compliance Officer Radhika Dammani	22-03-03	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Kabra Drugs Limited

Equities

524322

INE323K01017

Summary

Filters